Bone marrow angiogenesis in multiple myeloma

Area of Science:

• Oncology
• Hematology
• Cell Biology

Background:

• Angiogenesis, the formation of new blood vessels, is a critical factor in the progression of multiple myeloma (MM).
• The transition from monoclonal gammopathy of undetermined significance (MGUS) to MM is associated with increased angiogenesis, potentially due to reduced angiostatic activity.
• The complex pathophysiology involves direct cytokine production by plasma cells and induction within the bone marrow microenvironment.

Purpose of the Study:

• To elucidate the multifaceted role of angiogenesis in multiple myeloma progression.
• To understand the contribution of plasma cells and the bone marrow microenvironment to MM-induced angiogenesis.
• To explore the prognostic significance of angiogenesis in multiple myeloma.

Main Methods:

• Review of existing literature on angiogenesis in multiple myeloma.
• Analysis of the molecular mechanisms driving angiogenesis in the MM microenvironment.
• Investigation of the role of various cell types, including plasma cells, stromal cells, endothelial cells, osteoclasts, and inflammatory cells.

Main Results:

• Plasma cells induce angiogenesis through direct secretion of angiogenic factors and by stimulating the bone marrow microenvironment.
• Stromal cells, endothelial cells, and osteoclasts contribute to angiogenesis by secreting factors that promote plasma cell growth, survival, and migration.
• Inflammatory cells and circulating endothelial precursor cells (EPCs) also support neovascularization, with EPCs potentially contributing to vasculogenesis.

Conclusions:

• Angiogenesis is a fundamental process in multiple myeloma progression with significant prognostic implications.
• The intricate interplay between plasma cells and the bone marrow microenvironment orchestrates MM-induced angiogenesis.
• Targeting angiogenesis presents a potential therapeutic strategy for multiple myeloma.